# Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

> **NCT03221634** · PHASE2 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Daratumumab

## Key facts

- **NCT ID:** NCT03221634
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-08-01
- **Primary completion:** 2019-03-20
- **Final completion:** 2021-06-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2019-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221634, "Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03221634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*